Museum Centre Vapriikki: Ancient DNA Reveals 800-year-old Family Link in Medieval Finland
Ancient DNA research led by the Museum Centre Vapriikki in Tampere, Finland, in collaboration with the universities of Turku and Helsinki, has produced new insights into kinship, health, and population continuity in medieval and early modern Finland. Published in the peer-reviewed journal iScience, the research presents results from 25 individuals in Finland – a significant result in a country where acidic soils often lead to poor preservation of bones and genetic material.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250807066724/en/
The woman’s grave in Vilusenharju, Tampere was discovered in 1962, and the man’s grave in Ristiänmäki, Pälkäne in 1982. Ancient DNA research has now revealed that the deceased were siblings. Illustrations by Veronika Paschenko. Photo by Vapriikki.
Researchers successfully recovered DNA from individuals buried between the 12th and 19th centuries at three cemeteries in the Tampere region. The study is part of Vapriikki’s research project that applies scientific methods to investigate the region’s past.
Family ties and genetic continuity
One of the study’s findings was the discovery of full siblings buried 30 kilometers apart. A woman buried in Tampere and a man in Pälkäne, both from the 12th century, were confirmed to be sister and brother.
“This provides tangible evidence of family connections between different communities,” says Dr. Ulla Nordfors, researcher at Vapriikki.
Comparisons with over 4,000 modern Finnish genomes from the Finnish Institute for Health and Welfare’s biobank revealed that the ancient individuals from Tampere region share the closest genetic affinities with people living in the same region today.
“These results point to a remarkable degree of genetic continuity in the area since at least the early Middle Ages,” says Sanni Peltola, a doctoral researcher at the University of Helsinki.
Additional genetic links were detected between Finnish individuals and previously published ancient genomes from Scandinavia and the Lake Ladoga region, providing evidence of mobility and cultural contacts in the Viking Age and beyond.
“Although the dataset is relatively small, the findings clearly show that medieval Finland was not isolated,” Peltola notes. “It was part of the wider networks of interaction that shaped northern Europe.”
Health and traits revealed
The analysis also recovered microbial DNA that sheds light on health in past populations. Bacteria in 13th-century dental calculus included species linked to both oral and systemic health. DNA from a post-medieval man revealed the presence of Treponema, a bacterial genus that includes the causative agent of syphilis.
Hereditary traits were also uncovered. Most individuals were lactose tolerant, like modern Finns, and a 12th-century man likely had corneal dystrophy, a degenerative eye disease that may have impaired his vision.
“Genes cannot capture the full complexity of a person and their life, but learning about health, traits, and family ties can help us see ancient people as individuals who once lived, felt, and experienced the world,” says Nordfors. “When interpreted within their archaeological and historical context, these details allow us to approach the past on a more human level.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250807066724/en/
Contacts
Ulla Nordfors, ulla.nordfors@tampere.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom